Evidence map›Paper›PMID 40916664›Full record

ArticleBiology open2025

Generation of mice with combined Hexa Gly269Ser KI or KO and Neu3 KO alleles to create new models of GM2 gangliosidoses.

Emily N Barker, Mehrafarin Ashiri, Jennifer T Saville, Richard Hemming, Nikolas Furletti, Shreya H Dhume, Shirley Yu, Elaine Anjos, Xiaoli Wu, Agnes Fresnoza and 7 more

Abstract read
In one paragraph

Article in Biology open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Emily N BarkerDepartment of Biochemistry and Medical Genetics, University of Manitoba, Winnipeg, CanadaR3T 2N2.
Mehrafarin AshiriDepartment of Biochemistry and Medical Genetics, University of Manitoba, Winnipeg, CanadaR3T 2N2.
Jennifer T SavilleGenetics and Molecular Pathology, SA Pathology at Women's and Children's Hospital, 72 King William Road, North Adelaide 5006, Australia.
Richard HemmingDepartment of Biochemistry and Medical Genetics, University of Manitoba, Winnipeg, CanadaR3T 2N2.ORCID 0000-0002-8521-1725
Nikolas FurlettiDepartment of Biochemistry and Medical Genetics, University of Manitoba, Winnipeg, CanadaR3T 2N2.
Shreya H DhumePhysiology & Pathophysiology, University of Manitoba, Winnipeg, CanadaR3T 2N2.ORCID 0000-0002-9841-3713
Shirley YuDepartment of Biochemistry and Medical Genetics, University of Manitoba, Winnipeg, CanadaR3T 2N2.ORCID 0000-0002-5383-9964
Elaine AnjosDepartment of Biochemistry and Medical Genetics, University of Manitoba, Winnipeg, CanadaR3T 2N2.
Xiaoli WuDepartment of Biochemistry and Medical Genetics, University of Manitoba, Winnipeg, CanadaR3T 2N2.
Agnes FresnozaDepartment of Biochemistry and Medical Genetics, University of Manitoba, Winnipeg, CanadaR3T 2N2.
David C MerzDepartment of Biochemistry and Medical Genetics, University of Manitoba, Winnipeg, CanadaR3T 2N2.
Mike JacksonDepartment of Biochemistry and Medical Genetics, University of Manitoba, Winnipeg, CanadaR3T 2N2.
Marc R Del BigioPathology, University of Manitoba, Winnipeg, CanadaR3T 2N2.
Tabrez J SiddiquiPhysiology & Pathophysiology, University of Manitoba, Winnipeg, CanadaR3T 2N2.
Maria FullerGenetics and Molecular Pathology, SA Pathology at Women's and Children's Hospital, 72 King William Road, North Adelaide 5006, Australia.
Brian L MarkDepartment of Biochemistry and Medical Genetics, University of Manitoba, Winnipeg, CanadaR3T 2N2.
Barbara Triggs-RaineDepartment of Biochemistry and Medical Genetics, University of Manitoba, Winnipeg, CanadaR3T 2N2.ORCID 0000-0003-4719-6779

Funding

Autism SpeaksCIHRNatural Sciences and Engineering Council of CanadaResearch Manitoba
6 · The paper itself

Abstract

The GM2 gangliosidoses are lysosomal storage disorders exhibiting a spectrum of neurological phenotypes ranging from childhood death to debilitating adult-onset neurological impairment. To date, no mouse model harbouring a specific human mutation causing GM2 gangliosidosis has been created. We used CRISPR/Cas9 to generate knockin (KI) mice with the common adult-onset Hexa Gly269Ser variant as well as knockout (KO) mice with Hexa mutations expected to cause complete HexA deficiency. We also created Neu3 KO alleles that combined with Hexa KO or KI alleles were expected to create acute and chronic models of GM2 gangliosidosis, respectively. However, both models accumulated GM2 ganglioside throughout the brain when compared to controls (CON), and exhibited progressive loss of reflexes, gait abnormalities, and premature death by 24 weeks of age. Although survival and behavioural phenotypes did not differ between KO and KI models, the KI model had substantial Hexa mRNA and evidence of GM2 turnover. This KI model will be useful for developing gene editing to correct the variant causing the Gly269Ser substitution and its novel biochemical phenotype suggests it may be suitable for testing therapies that treat partial β-hexosaminidase A deficiency.

Indexed as

Allelesbeta-Hexosaminidase alpha ChainDisease Models, AnimalGangliosidoses, GM2AnimalsCRISPR-Cas SystemsGene Knock-In TechniquesHumansMiceMice, KnockoutMutationN-AcetylgalactosaminyltransferasesPhenotypebeta-Hexosaminidase alpha ChainN-Acetylgalactosaminyltransferases(N-acetylneuraminyl)-galactosylglucosylceramide N-acetylgalactosaminyltransferaseAdult onsetGM2 gangliosidosisHexaMouse modelNeu3Tay-Sachs disease

Identifiers

PMID40916664
PMCPMC12519549

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.